Literature DB >> 25167786

Common variant in the glucokinase regulatory gene rs780094 and risk of nonalcoholic fatty liver disease: a meta-analysis.

Shamsul Mohd Zain1, Zahurin Mohamed, Rosmawati Mohamed.   

Abstract

BACKGROUND AND AIM: Although studies have suggested that rs780094, a common variant in the glucokinase regulatory (GCKR) gene to be associated with type 2 diabetes, obesity, and their related traits, the genetic basis of the association between GCKR rs780094 and nonalcoholic fatty liver disease (NAFLD) is still being examined. This meta-analysis was performed to evaluate the effect strength caused by GCKR rs780094 on NAFLD.
METHODS: We searched Medline, PubMed, Scopus, and Embase for relevant articles published up to April 2014. Data were extracted, and summary estimates of the association between GCKR rs780094 and NAFLD were examined. Heterogeneity and publication bias were also examined.
RESULTS: This meta-analysis incorporated a total of 2091 NAFLD cases and 3003 controls from five studies. Overall, the pooled result indicated that the GCKR rs780094 was significantly associated with increased risk of NAFLD (additive: odds ratio (OR) 1.25, 95% confidence interval (CI) 1.14-1.36, P < 0.00001). Analysis also revealed significant associations with different alternative genetic models for the inheritance: dominant, recessive, and homozygote (OR 1.40, 95%CI 1.23-1.61, P < 0.00001; OR 0.79, 95% CI 0.68-0.91, P = 0.001, and; (OR 1.27, 95% CI 1.10-1.47, P = 0.001, respectively), but not the heterozygote model. Population subgroup analysis demonstrated similar effect size in both Asians and non-Asians (OR 1.27, 95%CI 1.12-1.45, P = 0.0003 and OR 1.22, 95%CI 1.10-1.37, P = 0.0003, respectively).
CONCLUSIONS: Our meta-analysis provides evidence of significant association between GCKR rs780094 and risk of NAFLD. Similar effect size was demonstrated in both Asian and non-Asian populations.
© 2014 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  GCKR; NAFLD; genetic variation; meta-analysis; rs780094

Mesh:

Substances:

Year:  2015        PMID: 25167786     DOI: 10.1111/jgh.12714

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  31 in total

Review 1.  Genetic background in nonalcoholic fatty liver disease: A comprehensive review.

Authors:  Fabio Salvatore Macaluso; Marcello Maida; Salvatore Petta
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 2.  The genetic backgrounds in nonalcoholic fatty liver disease.

Authors:  Yuya Seko; Kanji Yamaguchi; Yoshito Itoh
Journal:  Clin J Gastroenterol       Date:  2018-02-28

Review 3.  Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis.

Authors:  Jia-Zhen Zhang; Jing-Jing Cai; Yao Yu; Zhi-Gang She; Hongliang Li
Journal:  Gene Expr       Date:  2019-04-22

Review 4.  Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research.

Authors:  Joost Willebrords; Isabel Veloso Alves Pereira; Michaël Maes; Sara Crespo Yanguas; Isabelle Colle; Bert Van Den Bossche; Tereza Cristina Da Silva; Cláudia Pinto Marques Souza de Oliveira; Wellington Andraus; Venâncio Avancini Alves; Bruno Cogliati; Mathieu Vinken
Journal:  Prog Lipid Res       Date:  2015-06-11       Impact factor: 16.195

5.  The impact of genetic risk on liver fibrosis in non-alcoholic fatty liver disease as assessed by magnetic resonance elastography.

Authors:  Veeral Ajmera; Amy Liu; Ricki Bettencourt; Debanjan Dhar; Lisa Richards; Rohit Loomba
Journal:  Aliment Pharmacol Ther       Date:  2021-05-11       Impact factor: 8.171

Review 6.  Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD.

Authors:  Sílvia Vilarinho; Veeral Ajmera; Melanie Zheng; Rohit Loomba
Journal:  Hepatology       Date:  2021-10       Impact factor: 17.298

7.  Blood transcriptome profiling as potential biomarkers of suboptimal health status: potential utility of novel biomarkers for predictive, preventive, and personalized medicine strategy.

Authors:  Hao Wang; Qiuyue Tian; Jie Zhang; Hongqi Liu; Jinxia Zhang; Weijie Cao; Xiaoyu Zhang; Xingang Li; Lijuan Wu; Manshu Song; Yuanyuan Kong; Wei Wang; Youxin Wang
Journal:  EPMA J       Date:  2021-04-20       Impact factor: 8.836

8.  The Impact of PNPLA3 rs738409 Genetic Polymorphism and Weight Gain ≥10 kg after Age 20 on Non-Alcoholic Fatty Liver Disease in Non-Obese Japanese Individuals.

Authors:  Kenichi Nishioji; Naomi Mochizuki; Masao Kobayashi; Mai Kamaguchi; Yoshio Sumida; Takeshi Nishimura; Kanji Yamaguchi; Hiroshi Kadotani; Yoshito Itoh
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

9.  Interactions of a PPARGC1A Variant and a PNPLA3 Variant Affect Nonalcoholic Steatohepatitis in Severely Obese Taiwanese Patients.

Authors:  Chi-Ming Tai; Chih-Kun Huang; Hung-Pin Tu; Jau-Chung Hwang; Ming-Lun Yeh; Chung-Feng Huang; Jee-Fu Huang; Chia-Yen Dai; Wan-Long Chuang; Ming-Lung Yu
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

Review 10.  A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease.

Authors:  Paola Dongiovanni; Luca Valenti
Journal:  Int J Mol Sci       Date:  2017-07-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.